v3.26.1
Revenue Recognition - Drug Discovery (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 01, 2020
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Net receivables   $ 21,391,000   $ 21,391,000   $ 83,041,000
Deferred revenue   63,000   63,000   72,000
BMGFT | Related Party            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Software contribution revenue recognition   921,000 $ 4,513,000 921,000 $ 8,357,000  
Net receivables   5,000,000   5,000,000   0
Software contribution   438,000 212,000 509,000 711,000  
Agreement with Gates Ventures, LLC            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Software contribution revenue recognition amount $ 11,000,000     11,000,000    
Software contribution revenue recognition   2,000,000 0 2,000,000 0  
Deferred income   0   0   0
Net receivables   0   0   0
July 2024 Agreement with Bill & Melinda Gates Foundation            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Software contribution revenue recognition   921,000 $ 4,513,000 921,000 8,357,000  
Deferred income   4,079,000   4,079,000   0
Net receivables   $ 5,000,000   5,000,000   $ 0
Drug discovery            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Milestone payment yet to be achieved       0 2,000,000  
Revenue recognized with milestones       $ 0 $ 1,067,000